These authors demonstrated that patients with inflamed tumors have a better prognosis both in terms of OS and PFS and, in particular, that patients with inflamed neoplasms and high expression of PD-L1 show a significant improvement in survival compared to patients with high expression of PD-L1 but non-inflamed tumors. This evidence concerns the gene CD274 and neoplasm.